HOME > News

We wish to inform you that law no. 196/03 protects people
and other subjects as concerns the use of personal details.
Edit email address
Invialid email
Email Sent
Accept privacy law
 
Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and...
Parma (Italy) – June 23, 2017 – Chiesi Farmaceutici S.p.A. (Chiesi Group), an international research-focused Healthcare Group, announces today that it has completed...
1/7
ARCHIVE NEWS
Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award
Special Mention to Holoclar at the Italian Galeno Award
COPD indication for Foster pMDI
Double-digit growth and internal expansion for the Chiesi Group